Clinical phenotypes and genetic features of hereditary transthyretin amyloidosis patients in China

Hereditary transthyretin amyloidosis (hATTR) is a progressive and fatal disease with heterogenous clinical presentations, limited diagnosis and poor prognosis. This retrospective analysis study aimed to report the genotypes and phenotypes of herediary transthyretin amyloidosis (hATTR) in Chinese thr...

Full description

Saved in:
Bibliographic Details
Published inOrphanet journal of rare diseases Vol. 17; no. 1; pp. 1 - 16
Main Authors He, Xinyue, Tian, Zhuang, Guan, Hongzhi, Zhang, Shuyang
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 02.09.2022
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Hereditary transthyretin amyloidosis (hATTR) is a progressive and fatal disease with heterogenous clinical presentations, limited diagnosis and poor prognosis. This retrospective analysis study aimed to report the genotypes and phenotypes of herediary transthyretin amyloidosis (hATTR) in Chinese through a systematic review of published literature. The systematic review included structured searches of peer-reviewed literature published from 2007 to 2020 of following online reference databases: PubMed, Web of Science and the literature database in China. Extracted data included sample size, personal information (sex, age, natural course, family history), mutation type, clinical milestones and reason of death. We described 126 Chinese patients with hereditary transthyretin amyloidosis identified through a systematic review of 30 studies. The most common genotype in the Chinese population was Gly83Arg (25, 19.8%), which most likely presented visual and neurological abnormalities without reported death. The second and third most common genotypes were Val30Met (20, 15.9%) and Val30Ala (10, 7.9%). Peripheral neurological manifestations (91, 72%) were dominant in 126 patients. The followed manifestation was autonomic neurological abnormalities (73, 58%). Half of the cases were reported to have visual disorders, and nearly one-third of the cases presented cardiac abnormalities. Among all 126 reported patients, 46.03% were classified as neurological type, 30.16% as mixed type and only 2.38% as cardiac type. In addition. Chinese patients were mostly early onset, with age of onset at 41.8 (SD: 8.9) years, and the median time from onset to death was 7.5 [IQR: 5.3] years. Patients with cardiac involvement had a shorter survival duration (log Rank (Mantel-Cox), [chl].sup.2 = 26.885, P < 0.001). This study focused on 126 Chinese hATTR patients obtained from a literature review. A total of 26 kinds of TTR mutations were found and the most common one was Gly83Arg. As for phenotype, 46.03% were classified as neurological type, 30.16% as mixed type and only 2.38% as cardiac type. Chinese hATTR patients were mostly early onset (AO 41.8 years), and the median time from onset to death was 7.5 years.
AbstractList Hereditary transthyretin amyloidosis (hATTR) is a progressive and fatal disease with heterogenous clinical presentations, limited diagnosis and poor prognosis. This retrospective analysis study aimed to report the genotypes and phenotypes of herediary transthyretin amyloidosis (hATTR) in Chinese through a systematic review of published literature.BACKGROUNDHereditary transthyretin amyloidosis (hATTR) is a progressive and fatal disease with heterogenous clinical presentations, limited diagnosis and poor prognosis. This retrospective analysis study aimed to report the genotypes and phenotypes of herediary transthyretin amyloidosis (hATTR) in Chinese through a systematic review of published literature.The systematic review included structured searches of peer-reviewed literature published from 2007 to 2020 of following online reference databases: PubMed, Web of Science and the literature database in China. Extracted data included sample size, personal information (sex, age, natural course, family history), mutation type, clinical milestones and reason of death.METHODSThe systematic review included structured searches of peer-reviewed literature published from 2007 to 2020 of following online reference databases: PubMed, Web of Science and the literature database in China. Extracted data included sample size, personal information (sex, age, natural course, family history), mutation type, clinical milestones and reason of death.We described 126 Chinese patients with hereditary transthyretin amyloidosis identified through a systematic review of 30 studies. The most common genotype in the Chinese population was Gly83Arg (25, 19.8%), which most likely presented visual and neurological abnormalities without reported death. The second and third most common genotypes were Val30Met (20, 15.9%) and Val30Ala (10, 7.9%). Peripheral neurological manifestations (91, 72%) were dominant in 126 patients. The followed manifestation was autonomic neurological abnormalities (73, 58%). Half of the cases were reported to have visual disorders, and nearly one-third of the cases presented cardiac abnormalities. Among all 126 reported patients, 46.03% were classified as neurological type, 30.16% as mixed type and only 2.38% as cardiac type. In addition. Chinese patients were mostly early onset, with age of onset at 41.8 (SD: 8.9) years, and the median time from onset to death was 7.5 [IQR: 5.3] years. Patients with cardiac involvement had a shorter survival duration (log Rank (Mantel-Cox), χ2 = 26.885, P < 0.001).RESULTSWe described 126 Chinese patients with hereditary transthyretin amyloidosis identified through a systematic review of 30 studies. The most common genotype in the Chinese population was Gly83Arg (25, 19.8%), which most likely presented visual and neurological abnormalities without reported death. The second and third most common genotypes were Val30Met (20, 15.9%) and Val30Ala (10, 7.9%). Peripheral neurological manifestations (91, 72%) were dominant in 126 patients. The followed manifestation was autonomic neurological abnormalities (73, 58%). Half of the cases were reported to have visual disorders, and nearly one-third of the cases presented cardiac abnormalities. Among all 126 reported patients, 46.03% were classified as neurological type, 30.16% as mixed type and only 2.38% as cardiac type. In addition. Chinese patients were mostly early onset, with age of onset at 41.8 (SD: 8.9) years, and the median time from onset to death was 7.5 [IQR: 5.3] years. Patients with cardiac involvement had a shorter survival duration (log Rank (Mantel-Cox), χ2 = 26.885, P < 0.001).This study focused on 126 Chinese hATTR patients obtained from a literature review. A total of 26 kinds of TTR mutations were found and the most common one was Gly83Arg. As for phenotype, 46.03% were classified as neurological type, 30.16% as mixed type and only 2.38% as cardiac type. Chinese hATTR patients were mostly early onset (AO 41.8 years), and the median time from onset to death was 7.5 years.CONCLUSIONSThis study focused on 126 Chinese hATTR patients obtained from a literature review. A total of 26 kinds of TTR mutations were found and the most common one was Gly83Arg. As for phenotype, 46.03% were classified as neurological type, 30.16% as mixed type and only 2.38% as cardiac type. Chinese hATTR patients were mostly early onset (AO 41.8 years), and the median time from onset to death was 7.5 years.
Background Hereditary transthyretin amyloidosis (hATTR) is a progressive and fatal disease with heterogenous clinical presentations, limited diagnosis and poor prognosis. This retrospective analysis study aimed to report the genotypes and phenotypes of herediary transthyretin amyloidosis (hATTR) in Chinese through a systematic review of published literature. Methods The systematic review included structured searches of peer-reviewed literature published from 2007 to 2020 of following online reference databases: PubMed, Web of Science and the literature database in China. Extracted data included sample size, personal information (sex, age, natural course, family history), mutation type, clinical milestones and reason of death. Results We described 126 Chinese patients with hereditary transthyretin amyloidosis identified through a systematic review of 30 studies. The most common genotype in the Chinese population was Gly83Arg (25, 19.8%), which most likely presented visual and neurological abnormalities without reported death. The second and third most common genotypes were Val30Met (20, 15.9%) and Val30Ala (10, 7.9%). Peripheral neurological manifestations (91, 72%) were dominant in 126 patients. The followed manifestation was autonomic neurological abnormalities (73, 58%). Half of the cases were reported to have visual disorders, and nearly one-third of the cases presented cardiac abnormalities. Among all 126 reported patients, 46.03% were classified as neurological type, 30.16% as mixed type and only 2.38% as cardiac type. In addition. Chinese patients were mostly early onset, with age of onset at 41.8 (SD: 8.9) years, and the median time from onset to death was 7.5 [IQR: 5.3] years. Patients with cardiac involvement had a shorter survival duration (log Rank (Mantel-Cox), χ2 = 26.885, P < 0.001). Conclusions This study focused on 126 Chinese hATTR patients obtained from a literature review. A total of 26 kinds of TTR mutations were found and the most common one was Gly83Arg. As for phenotype, 46.03% were classified as neurological type, 30.16% as mixed type and only 2.38% as cardiac type. Chinese hATTR patients were mostly early onset (AO 41.8 years), and the median time from onset to death was 7.5 years.
Hereditary transthyretin amyloidosis (hATTR) is a progressive and fatal disease with heterogenous clinical presentations, limited diagnosis and poor prognosis. This retrospective analysis study aimed to report the genotypes and phenotypes of herediary transthyretin amyloidosis (hATTR) in Chinese through a systematic review of published literature. The systematic review included structured searches of peer-reviewed literature published from 2007 to 2020 of following online reference databases: PubMed, Web of Science and the literature database in China. Extracted data included sample size, personal information (sex, age, natural course, family history), mutation type, clinical milestones and reason of death. We described 126 Chinese patients with hereditary transthyretin amyloidosis identified through a systematic review of 30 studies. The most common genotype in the Chinese population was Gly83Arg (25, 19.8%), which most likely presented visual and neurological abnormalities without reported death. The second and third most common genotypes were Val30Met (20, 15.9%) and Val30Ala (10, 7.9%). Peripheral neurological manifestations (91, 72%) were dominant in 126 patients. The followed manifestation was autonomic neurological abnormalities (73, 58%). Half of the cases were reported to have visual disorders, and nearly one-third of the cases presented cardiac abnormalities. Among all 126 reported patients, 46.03% were classified as neurological type, 30.16% as mixed type and only 2.38% as cardiac type. In addition. Chinese patients were mostly early onset, with age of onset at 41.8 (SD: 8.9) years, and the median time from onset to death was 7.5 [IQR: 5.3] years. Patients with cardiac involvement had a shorter survival duration (log Rank (Mantel-Cox), [chl].sup.2 = 26.885, P < 0.001). This study focused on 126 Chinese hATTR patients obtained from a literature review. A total of 26 kinds of TTR mutations were found and the most common one was Gly83Arg. As for phenotype, 46.03% were classified as neurological type, 30.16% as mixed type and only 2.38% as cardiac type. Chinese hATTR patients were mostly early onset (AO 41.8 years), and the median time from onset to death was 7.5 years.
Abstract Background Hereditary transthyretin amyloidosis (hATTR) is a progressive and fatal disease with heterogenous clinical presentations, limited diagnosis and poor prognosis. This retrospective analysis study aimed to report the genotypes and phenotypes of herediary transthyretin amyloidosis (hATTR) in Chinese through a systematic review of published literature. Methods The systematic review included structured searches of peer-reviewed literature published from 2007 to 2020 of following online reference databases: PubMed, Web of Science and the literature database in China. Extracted data included sample size, personal information (sex, age, natural course, family history), mutation type, clinical milestones and reason of death. Results We described 126 Chinese patients with hereditary transthyretin amyloidosis identified through a systematic review of 30 studies. The most common genotype in the Chinese population was Gly83Arg (25, 19.8%), which most likely presented visual and neurological abnormalities without reported death. The second and third most common genotypes were Val30Met (20, 15.9%) and Val30Ala (10, 7.9%). Peripheral neurological manifestations (91, 72%) were dominant in 126 patients. The followed manifestation was autonomic neurological abnormalities (73, 58%). Half of the cases were reported to have visual disorders, and nearly one-third of the cases presented cardiac abnormalities. Among all 126 reported patients, 46.03% were classified as neurological type, 30.16% as mixed type and only 2.38% as cardiac type. In addition. Chinese patients were mostly early onset, with age of onset at 41.8 (SD: 8.9) years, and the median time from onset to death was 7.5 [IQR: 5.3] years. Patients with cardiac involvement had a shorter survival duration (log Rank (Mantel-Cox), χ2 = 26.885, P < 0.001). Conclusions This study focused on 126 Chinese hATTR patients obtained from a literature review. A total of 26 kinds of TTR mutations were found and the most common one was Gly83Arg. As for phenotype, 46.03% were classified as neurological type, 30.16% as mixed type and only 2.38% as cardiac type. Chinese hATTR patients were mostly early onset (AO 41.8 years), and the median time from onset to death was 7.5 years.
Background Hereditary transthyretin amyloidosis (hATTR) is a progressive and fatal disease with heterogenous clinical presentations, limited diagnosis and poor prognosis. This retrospective analysis study aimed to report the genotypes and phenotypes of herediary transthyretin amyloidosis (hATTR) in Chinese through a systematic review of published literature. Methods The systematic review included structured searches of peer-reviewed literature published from 2007 to 2020 of following online reference databases: PubMed, Web of Science and the literature database in China. Extracted data included sample size, personal information (sex, age, natural course, family history), mutation type, clinical milestones and reason of death. Results We described 126 Chinese patients with hereditary transthyretin amyloidosis identified through a systematic review of 30 studies. The most common genotype in the Chinese population was Gly83Arg (25, 19.8%), which most likely presented visual and neurological abnormalities without reported death. The second and third most common genotypes were Val30Met (20, 15.9%) and Val30Ala (10, 7.9%). Peripheral neurological manifestations (91, 72%) were dominant in 126 patients. The followed manifestation was autonomic neurological abnormalities (73, 58%). Half of the cases were reported to have visual disorders, and nearly one-third of the cases presented cardiac abnormalities. Among all 126 reported patients, 46.03% were classified as neurological type, 30.16% as mixed type and only 2.38% as cardiac type. In addition. Chinese patients were mostly early onset, with age of onset at 41.8 (SD: 8.9) years, and the median time from onset to death was 7.5 [IQR: 5.3] years. Patients with cardiac involvement had a shorter survival duration (log Rank (Mantel-Cox), [chl].sup.2 = 26.885, P < 0.001). Conclusions This study focused on 126 Chinese hATTR patients obtained from a literature review. A total of 26 kinds of TTR mutations were found and the most common one was Gly83Arg. As for phenotype, 46.03% were classified as neurological type, 30.16% as mixed type and only 2.38% as cardiac type. Chinese hATTR patients were mostly early onset (AO 41.8 years), and the median time from onset to death was 7.5 years. Keywords: Transthyretin amyloidosis, Rare disease, Hereditary, Chinese
ArticleNumber 337
Audience Academic
Author Zhang, Shuyang
Guan, Hongzhi
Tian, Zhuang
He, Xinyue
Author_xml – sequence: 1
  givenname: Xinyue
  surname: He
  fullname: He, Xinyue
– sequence: 2
  givenname: Zhuang
  orcidid: 0000-0003-1140-4062
  surname: Tian
  fullname: Tian, Zhuang
– sequence: 3
  givenname: Hongzhi
  surname: Guan
  fullname: Guan, Hongzhi
– sequence: 4
  givenname: Shuyang
  surname: Zhang
  fullname: Zhang, Shuyang
BookMark eNp9kl1r2zAUhs3oWNtsf2BXht1sF-70ZUu6GZSwdoHCYB_XQpGPEwVHyiS5LP9-J03ZljKGETZHz3l93sN7WZ2FGKCqXlNyRanq3mfKCeMNYQyPULTRz6oLKlvSUCrZ2V_f59VlzhtCRMuJelGd8460neDsolrORx-8s2O9W0OIZb-DXNvQ1ysIULyrB7BlSliMQ72GBL0vNu3rkmzIZb1PCIXabvdj9H3MPtc7WzyEkmusz9c-2JfV88GOGV49vmfV95uP3-afmrvPt4v59V3jWilKMyhGmRAdlbRrW6I1EDL0rLUDZYRKIRRnUvG25z1zSi-p1IIT2WnROSWWms-qxVG3j3ZjdslvcVATrTcPhZhWxia0NIIRTjBriVrKHgThWjuiOqAg2dBphVuaVR-OWrtpuYXeoaFkxxPR05vg12YV7w3OpDihKPD2USDFHxPkYrY-OxhHGyBO2TBJtOTohyD65gm6iVMKuCqkaCsk-tZ_qJVFAz4MEf_rDqLmGjdGOMUcIHX1DwqfHrbeYXwGj_WThncnDcgU-FlWdsrZLL5-OWXZkXUp5pxg-L0PSswhkeaYSIOweUikOcytnjQ5TFDx8bA3P_6v9RfPAOIq
CitedBy_id crossref_primary_10_1016_j_hfc_2024_03_006
crossref_primary_10_1080_13506129_2024_2383467
crossref_primary_10_1016_S1634_7072_24_50005_8
crossref_primary_10_3390_jpm15020061
crossref_primary_10_1002_ana_27203
crossref_primary_10_3389_fneur_2024_1471131
Cites_doi 10.1007/s00415-018-9125-z
10.1016/j.jocn.2018.10.040
10.1186/2046-4053-4-1
10.1097/MD.0000000000016566
10.1007/s12035-017-0694-0
10.1002/mus.26034
10.1097/MD.0000000000005737
10.3109/13506129.2014.892871
10.1038/srep26362
10.1080/13506129.2017.1292902
10.3109/13816810.2011.599356
10.1093/eurheartj/ehz173
10.1016/S1001-9294(09)60044-4
10.1016/j.jns.2011.02.005
10.1111/jns.12196
10.1136/jnnp-2014-308724
10.1016/j.exer.2013.02.005
10.1186/s13023-019-1000-1
10.1159/000321679
10.1038/eye.2013.217
10.1111/aos.13425
10.4103/0366-6999.168048
10.1038/eye.2014.10
10.1007/s00018-019-03357-1
10.1080/13506120802193720
10.1212/WNL.0b013e318248df18
10.1007/s11684-017-0516-9
10.1016/j.jacc.2016.03.596
ContentType Journal Article
Copyright COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022. The Author(s).
The Author(s) 2022
Copyright_xml – notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022. The Author(s).
– notice: The Author(s) 2022
DBID AAYXX
CITATION
ISR
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AN0
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13023-022-02481-9
DatabaseName CrossRef
Gale In Context: Science
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
British Nursing Database
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Proquest Medical Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
British Nursing Index with Full Text
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Publicly Available Content Database




Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1750-1172
EndPage 16
ExternalDocumentID oai_doaj_org_article_4c42aa08b7de40399c086e1e72f69845
PMC9438301
A716031022
10_1186_s13023_022_02481_9
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: ;
– fundername: ;
  grantid: CIFMS 2021-I2M-1-003
GroupedDBID ---
0R~
123
29N
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AN0
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BNQBC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ISR
ITC
KQ8
M1P
M48
MK0
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
WOQ
WOW
~8M
PMFND
3V.
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c574t-f8212446171655099e00fd25af12017448327835d3d2c89b17943076946c84b93
IEDL.DBID M48
ISSN 1750-1172
IngestDate Wed Aug 27 01:28:30 EDT 2025
Thu Aug 21 18:45:49 EDT 2025
Thu Jul 10 18:20:36 EDT 2025
Fri Jul 25 07:35:21 EDT 2025
Tue Jun 17 21:49:17 EDT 2025
Tue Jun 10 20:48:48 EDT 2025
Fri Jun 27 04:25:35 EDT 2025
Thu Apr 24 23:16:23 EDT 2025
Tue Jul 01 02:23:31 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c574t-f8212446171655099e00fd25af12017448327835d3d2c89b17943076946c84b93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ORCID 0000-0003-1140-4062
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s13023-022-02481-9
PMID 36056432
PQID 2715473279
PQPubID 76088
PageCount 16
ParticipantIDs doaj_primary_oai_doaj_org_article_4c42aa08b7de40399c086e1e72f69845
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9438301
proquest_miscellaneous_2709737830
proquest_journals_2715473279
gale_infotracmisc_A716031022
gale_infotracacademiconefile_A716031022
gale_incontextgauss_ISR_A716031022
crossref_primary_10_1186_s13023_022_02481_9
crossref_citationtrail_10_1186_s13023_022_02481_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-09-02
PublicationDateYYYYMMDD 2022-09-02
PublicationDate_xml – month: 09
  year: 2022
  text: 2022-09-02
  day: 02
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Orphanet journal of rare diseases
PublicationYear 2022
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References Y Sekijima (2481_CR1) 2015; 86
U Hellman (2481_CR39) 2008; 15
J Fan (2481_CR23) 2014; 42
J Xu (2481_CR33) 2017; 96
LC Meng (2481_CR2) 2015; 128
LA Jones (2481_CR42) 1991; 48
X Zou (2481_CR22) 2013; 110
T Yamashita (2481_CR5) 2012; 78
H Chen (2481_CR16) 2016; 6
BL Hu (2481_CR37) 2018; 35
H Guan (2481_CR19) 2015; 48
JY Liu (2481_CR17) 2011; 304
B Xie (2481_CR11) 2017; 95
K Fan (2481_CR24) 2019; 266
T Damy (2481_CR6) 2019; 43
Y Zhang (2481_CR35) 2011; 8
MW Cruz (2481_CR3) 2017; 24
J Xi (2481_CR30) 2010; 18
G Liu (2481_CR32) 2017; 22
M Waddington-Cruz (2481_CR41) 2019; 14
AM Zhang (2481_CR12) 2013; 19
YF Li (2481_CR13) 2008; 23
D Long (2481_CR21) 2012; 33
D Hu (2481_CR27) 2017; 11
J Yin (2481_CR9) 2014; 21
RB Ibrahim (2481_CR40) 2020; 77
MS Maurer (2481_CR38) 2016; 68
T Liu (2481_CR10) 2014; 28
K Fan (2481_CR25) 2019; 266
W Lv (2481_CR15) 2014; 28
LY Chen (2481_CR8) 2011; 4
Z Yuan (2481_CR29) 2019; 60
PW Zhu (2481_CR14) 2017; 35
D Moher (2481_CR7) 2015; 4
HH Schmidt (2481_CR4) 2018; 57
G Liu (2481_CR20) 2017; 22
Q Chen (2481_CR26) 2018; 55
J Qin (2481_CR28) 2019; 98
2481_CR34
2481_CR31
X Miao (2481_CR36) 2010; 17
MJ Xu (2481_CR18) 2007; 40
References_xml – volume: 35
  start-page: 555
  issue: 06
  year: 2018
  ident: 2481_CR37
  publication-title: J Apoplexy Nervous Dis
– volume: 266
  start-page: 232
  issue: 1
  year: 2019
  ident: 2481_CR24
  publication-title: J Neurol
  doi: 10.1007/s00415-018-9125-z
– volume: 60
  start-page: 164
  year: 2019
  ident: 2481_CR29
  publication-title: J Clin Neurosci.
  doi: 10.1016/j.jocn.2018.10.040
– volume: 4
  start-page: 1
  year: 2015
  ident: 2481_CR7
  publication-title: Syst Rev
  doi: 10.1186/2046-4053-4-1
– volume: 98
  issue: 30
  year: 2019
  ident: 2481_CR28
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000016566
– volume: 35
  start-page: 181
  issue: 03
  year: 2017
  ident: 2481_CR14
  publication-title: Chin J Clin Lab Sci
– volume: 55
  start-page: 4911
  issue: 6
  year: 2018
  ident: 2481_CR26
  publication-title: Mol Neurobiol
  doi: 10.1007/s12035-017-0694-0
– volume: 57
  start-page: 829
  issue: 5
  year: 2018
  ident: 2481_CR4
  publication-title: Muscle Nerve
  doi: 10.1002/mus.26034
– volume: 96
  start-page: e5737
  issue: 10
  year: 2017
  ident: 2481_CR33
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000005737
– volume: 21
  start-page: 140
  issue: 2
  year: 2014
  ident: 2481_CR9
  publication-title: Amyloid
  doi: 10.3109/13506129.2014.892871
– volume: 6
  start-page: 26362
  year: 2016
  ident: 2481_CR16
  publication-title: Sci Rep
  doi: 10.1038/srep26362
– volume: 24
  start-page: 109
  issue: sup1
  year: 2017
  ident: 2481_CR3
  publication-title: Amyloid
  doi: 10.1080/13506129.2017.1292902
– volume: 33
  start-page: 28
  issue: 1
  year: 2012
  ident: 2481_CR21
  publication-title: Ophthalmic Genet
  doi: 10.3109/13816810.2011.599356
– volume: 43
  start-page: 391
  year: 2019
  ident: 2481_CR6
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehz173
– volume: 23
  start-page: 230
  issue: 4
  year: 2008
  ident: 2481_CR13
  publication-title: Chin Med Sci J
  doi: 10.1016/S1001-9294(09)60044-4
– volume: 48
  start-page: 7
  issue: 01
  year: 2015
  ident: 2481_CR19
  publication-title: Chin J Neurol
– volume: 304
  start-page: 83
  issue: 1–2
  year: 2011
  ident: 2481_CR17
  publication-title: J Neurol Sci
  doi: 10.1016/j.jns.2011.02.005
– ident: 2481_CR34
– volume: 22
  start-page: 19
  issue: 1
  year: 2017
  ident: 2481_CR20
  publication-title: J Peripher Nervous Syst
  doi: 10.1111/jns.12196
– volume: 86
  start-page: 1036
  issue: 9
  year: 2015
  ident: 2481_CR1
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp-2014-308724
– volume: 22
  start-page: 19
  issue: 1
  year: 2017
  ident: 2481_CR32
  publication-title: J Peripher Nerv Syst
  doi: 10.1111/jns.12196
– volume: 4
  start-page: 329
  issue: 3
  year: 2011
  ident: 2481_CR8
  publication-title: Int J Ophthalmol
– volume: 48
  start-page: 979
  issue: 5
  year: 1991
  ident: 2481_CR42
  publication-title: Am J Hum Genet
– volume: 40
  start-page: 173
  issue: 03
  year: 2007
  ident: 2481_CR18
  publication-title: Chin J Neurol
– volume: 110
  start-page: 44
  year: 2013
  ident: 2481_CR22
  publication-title: Exp Eye Res
  doi: 10.1016/j.exer.2013.02.005
– volume: 42
  start-page: 784
  issue: 9
  year: 2014
  ident: 2481_CR23
  publication-title: Zhonghua Xin Xue Guan Bing Za Zhi
– volume: 14
  start-page: 34
  issue: 1
  year: 2019
  ident: 2481_CR41
  publication-title: Orphanet J Rare Dis
  doi: 10.1186/s13023-019-1000-1
– volume: 8
  start-page: 187
  issue: 4
  year: 2011
  ident: 2481_CR35
  publication-title: Neurodegener Dis
  doi: 10.1159/000321679
– volume: 28
  start-page: 26
  issue: 1
  year: 2014
  ident: 2481_CR10
  publication-title: Eye (Lond)
  doi: 10.1038/eye.2013.217
– volume: 95
  start-page: e520
  issue: 6
  year: 2017
  ident: 2481_CR11
  publication-title: Acta Ophthalmol
  doi: 10.1111/aos.13425
– volume: 128
  start-page: 2902
  issue: 21
  year: 2015
  ident: 2481_CR2
  publication-title: Chin Med J (Engl)
  doi: 10.4103/0366-6999.168048
– volume: 28
  start-page: 452
  issue: 4
  year: 2014
  ident: 2481_CR15
  publication-title: Eye (Lond)
  doi: 10.1038/eye.2014.10
– volume: 17
  start-page: 956
  year: 2010
  ident: 2481_CR36
  publication-title: Chin J Integr Med Cardiocerebrovasc Dis
– volume: 77
  start-page: 1421
  issue: 7
  year: 2020
  ident: 2481_CR40
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-019-03357-1
– volume: 266
  start-page: 232
  issue: 1
  year: 2019
  ident: 2481_CR25
  publication-title: J Neurol
  doi: 10.1007/s00415-018-9125-z
– volume: 18
  start-page: 401
  issue: 04
  year: 2010
  ident: 2481_CR30
  publication-title: Chin J Clin Neurosci
– volume: 15
  start-page: 181
  issue: 3
  year: 2008
  ident: 2481_CR39
  publication-title: Amyloid
  doi: 10.1080/13506120802193720
– volume: 19
  start-page: 1631
  year: 2013
  ident: 2481_CR12
  publication-title: Mol Vis.
– volume: 78
  start-page: 637
  issue: 9
  year: 2012
  ident: 2481_CR5
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e318248df18
– ident: 2481_CR31
– volume: 11
  start-page: 293
  issue: 2
  year: 2017
  ident: 2481_CR27
  publication-title: Front Med
  doi: 10.1007/s11684-017-0516-9
– volume: 68
  start-page: 161
  issue: 2
  year: 2016
  ident: 2481_CR38
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2016.03.596
SSID ssj0045308
Score 2.3984413
Snippet Hereditary transthyretin amyloidosis (hATTR) is a progressive and fatal disease with heterogenous clinical presentations, limited diagnosis and poor prognosis....
Background Hereditary transthyretin amyloidosis (hATTR) is a progressive and fatal disease with heterogenous clinical presentations, limited diagnosis and poor...
Abstract Background Hereditary transthyretin amyloidosis (hATTR) is a progressive and fatal disease with heterogenous clinical presentations, limited diagnosis...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1
SubjectTerms Age
Amyloidosis
Autonomic nervous system
Cardiomyopathy
Chinese
Death
Family medical history
Genotype & phenotype
Genotypes
Heart
Hereditary
Identification and classification
Literature reviews
Medical prognosis
Medical research
Mutation
Patients
Peripheral neuropathy
Phenotype
Phenotypes
Rare disease
Rare diseases
Survival analysis
Systematic review
Transthyretin
Transthyretin amyloidosis
Vision
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9UwDI_QDogL4lMUtikgJA6oWpqm-ThuE9NAGgdg0m5R2ibsSVuLlr4D__3sNO9pHRJcuDaO2thObDf2z4S816YVtRSs7LWqSwQkL01gvnQNOssmSOGxOPnsqzw9F18umos7rb4wJ2yGB54ZdyA6wZ1julW9FwzMaQdOuK-84kEaLRJ6Kdi8TTA1n8GiqZnelMhoeRDxeg7vK3mJGF5VaRZmKKH1_3km38-TvGN4Tp6Qx9ljpIfzlz4lD_zwjDw8y3fiz0mboT2vKKZrjfhPNVI39BRUAysUafAJvDPSMdBLbM25mtzNbzqhlQIxYRnjQN01RO6rfoyrSDPWaqTwPPXXfkHOTz79OD4tc-eEsmuUmMqgOdptiVg4EIIY4xkLPW9cqMDgKwjJauyw0fR1zzsQV4KJY0oaITstWlO_JDvDOPhXhLaIUW90qERbC4cOeQidb7XrtVRg_gtSbRhpuwwrjt0trmwKL7S0M_MtMN8m5ltTkI_bOb9mUI2_Uh-hfLaUCIidHoCa2Kwm9l9qUpB3KF2LkBcD5tT8dOsY7efv3-yhSq224Y0F-ZCJwghr6FwuUQBOIErWgnJ3QQl7slsOb5TI5jMhWq4qbPTMFazo7XYYZ2Ke2-DHNdIgfBKIhhVELZRvsfzlyLC6TLjgBmFnWfX6f_DrDXnE03YxsGN2yc50s_Z74H5N7X7aabf9fSjC
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4ilCCzIIiQOymjhObJ9QQVQFqRyASnuzHMduVypJWWcP_ffMeL0LAanXeKwk87Bn7JlvCHmjdCfqVpSsV7JmCEjOdCg9sw06yzq0wmNx8unX9uRMfFk0i3zgFnNa5XZNTAt1Pzo8Iz_kssI2uVzq91e_GHaNwtvV3ELjNrmD0GWo1XKxC7hEU5dqWyij2sOIl3R4a8kZInlVTM82o4TZ___K_G-25F_bz_EDcj_7jfRoI-iH5JYfHpG7p_lm_DHpMsDnJcWkrRFPViO1Q09BQbBOkQafIDwjHQO9wAady8murumEexUIC4sZB2p_Qvy-7Me4jDQjrkYKz1OX7Sfk7PjTj48nLPdPYK6RYmJBcdy9W0TEgUBEa1-WoeeNDRVs-xICsxr7bDR93XMHQktgcaVstWidEp2un5K9YRz8M0I7RKrXKlSiq4VFtzwE5ztle9VKcAIKUm0ZaVwGF8ceF5cmBRmqNRvmG2C-Scw3uiDvdnOuNtAaN1J_QPnsKBEWOz0YV-cmW5kRTnALn9fJ3osSfC8HEZuvvOQBvl40BXmN0jUIfDFgZs25XcdoPn__Zo5kargNbyzI20wURvgHZ3OhAnACsbJmlAczSrBMNx_eKpHJK0M0f_S4IK92wzgTs90GP66RBkGUQDRlQeRM-Wa_Px8ZlhcJHVwj-GxZPb_55fvkHk-GoMEWDsjetFr7F-BeTd3LZEO_AR98IOI
  priority: 102
  providerName: ProQuest
Title Clinical phenotypes and genetic features of hereditary transthyretin amyloidosis patients in China
URI https://www.proquest.com/docview/2715473279
https://www.proquest.com/docview/2709737830
https://pubmed.ncbi.nlm.nih.gov/PMC9438301
https://doaj.org/article/4c42aa08b7de40399c086e1e72f69845
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9NAEB_uA8QX8ROjZ1lF8EFW87HJZh9EenLHWeghdxb6tuRj965QE21S8P57Z7bbYvQQfCpkJ212Zqczk935_QBe56oUSSZCXucy4QRIzpUNDS9SSpaVzYSh5uTpeXY2E5N5Ot-DLd2RV2B3a2lHfFKz1fLdzx83H9HhPziHz7P3HW2-0W5kzAmhK-JqHw4xMkliNJiK3a6CSBPHUIcRM-QRDm-baG79jkGgcnj-f_9r_3mS8rfQdHof7vmcko03i-AB7JnmIdyZ-l3zR1B68M8lowNdLb117VjR1AwXD_UwMmscvGfHWsuuibxz0RerG9ZTHENDUqNjw4pvWNsv6rZbdMyjsXYMrzsG7scwOz35-umMe24FXqVS9NzmMUX2jNBysEhRyoShreO0sBGmBBKLtoQ4ONI6qeMKDeqA5EKZKZFVuShV8gQOmrYxT4GVhGKvchuJMhEFpezWVqbMizrPJJohgGirSF154HHiv1hqV4Dkmd4oX6PytVO-VgG83d3zfQO78U_pY7LPTpIgs92FdnWlvQdqUYm4wMcrZW1EiHlZhdWciYyMLT69SAN4RdbVBIrR0Kmbq2Lddfrz5YUeS0fGjb8YwBsvZFucQ1X4JgbUBOFoDSSPBpLotdVweLuI9HbR61hGRAUdS5zRy90w3Ukn4RrTrkmGAJbQNGEAcrD4BtMfjjSLa4ccrgiYNoye_Zd2n8Pd2PmFQtc4goN-tTYvMBPryxHsy7kcweF4PLmc4OfxyfmXi5F7rzFyrvcLL70ukA
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIgEXVF4iUMAgEAdkNXGcOD4gVB7VLu32AK20N5M4drvSkrSbrND-KX4jM95kISD11ms8UeLxjGfGnvmGkFeZKkScipCVmYwZApIz5ULL8gSdZeVSYbE4eXKcjk7Fl2ky3SK_-loYTKvs90S_UZe1wTPyPS4jbJPLpXp_ccmwaxTervYtNNZicWhXPyFka96NP8H6vub84PPJxxHrugowk0jRMpdxtGkp4sSAe66UDUNX8iR3ERhDCeFKjN0nkjIuuYGpeAg1iPaVSE0mCgRfgi3_BhjeEIM9Od0EeCKJw6wvzMnSvQYvBfGWlDNEDouYGhg_3yPgf0vwb3bmX-buYIfc6fxUur8WrLtky1b3yM1JdxN_nxQdoOicYpJYjSe5Dc2rkoJAYl0kddZDhja0dvQcG4LO2nyxoi3aRhAOLJ6saP5jNa9nZd3MGtohvDYUnvuu3g_I6bVw9iHZrurKPiK0QGR8lblIFLHIMQxwztgiy8ssleB0BCTqGalNB2aOPTXm2gc1WarXzNfAfO2Zr1VA3m7euVhDeVxJ_QHXZ0OJMNz-Qb04051Wa2EEz-H3CllaEYKvZyBCtJGV3MHfiyQgL3F1NQJtVJjJc5Yvm0aPv33V-9I3-IYvBuRNR-RqmIPJu8II4ARicw0odweUsBOY4XAvRLrbiRr9R28C8mIzjG9idl1l6yXSIGgTLE0YEDkQvsH0hyPV7NyjkSsEuw2jx1d__Dm5NTqZHOmj8fHhE3Kbe6VQoBe7ZLtdLO1TcO3a4pnXJ0q-X7cC_wYnMFkp
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+phenotypes+and+genetic+features+of+hereditary+transthyretin+amyloidosis+patients+in+China&rft.jtitle=Orphanet+journal+of+rare+diseases&rft.au=He%2C+Xinyue&rft.au=Tian%2C+Zhuang&rft.au=Guan%2C+Hongzhi&rft.au=Zhang%2C+Shuyang&rft.date=2022-09-02&rft.issn=1750-1172&rft.eissn=1750-1172&rft.volume=17&rft.issue=1&rft_id=info:doi/10.1186%2Fs13023-022-02481-9&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s13023_022_02481_9
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-1172&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-1172&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-1172&client=summon